Research - Even with Alexion Pharmaceuticals (ALXN) announcing Wednesday morning the acquisition of Synageva (GEVA) for a heady $8 billion, aggressive dip-buyers are still absent in the … Continue Reading
PremiumInsights - A week after the FDA modified a similar restriction on Tekmira Pharmaceuticals (TKMR), the federal agency has cleared Arrowhead Research (ARWR) to proceed with a multiple-dose Phase 2b clinical study … Continue Reading
Read nowResearch - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read nowInsights - That's what Regeneron (REGN) and Sanofi (SNY) paid for a FDA Priority Review Voucher that will shorten the review time for the PCSK9 inhibitor, alirocumab.
Read nowRecap - The markets have rebounded precipitously from lows this October, with both the S&P 500 and iShares NASDAQ Biotechnology Index (IBB) making new all-time highs in the … Continue Reading
Read now
